Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979805339> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2979805339 endingPage "S1589" @default.
- W2979805339 startingPage "S1589" @default.
- W2979805339 abstract "INTRODUCTION: Vedolizumab is an anti-integrin therapy for IBD. It is a monoclonal antibody that selectively inhibits the interaction between the MAdCAM-1 receptor and α4β7 integrin in the gut. Vedolizumab, in comparison to other biologics, has a smaller pool of literature designating it's safety profile, specifically in the elderly (age >65 years of age) population of IBD patients. The GEMINI post-hoc trials have indicated an acceptable rate of infections, adverse reactions leading to hospitalization, and rate of malignancy in patients older than 55 years of age. The elderly subset of patients, designated as those 60-65 years of age or older by prior literature, is a growing population in need of effective and safe treatment of their IBD. METHODS: We searched the Epic database for Lahey patients with a diagnosis of inflammatory bowel disease, searching for patients who had been prescribed vedolizumab for this diagnosis. Of the compiled list of patients collected with these criteria, we searched the patient charts for the occurrence of flares, infections, development of malignancy, and death. Reasons for exclusion from the study include discontinuation of vedolizumab before completion of induction dosing, not being on vedolizumab, and lack of gastroenterology follow-up at Lahey Medical Center by a Lahey gastroenterologist. RESULTS: Of a total of 86 patients with IBD, ages ranging from 23-81 years of age, there was no significant difference found in the time to flare, time to remission from flare, incidence of infections, arthralgias, or malignancy in patients with IBD >65 after starting vedolizumab. Non-melanomatous skin cancer was the most common malignancy diagnosed after starting vedolizumab in both groups. CONCLUSION: Our data indicated no statistical difference between the adverse reactions leading to hospitalization, time to flare, and malignancy between the elderly and non-elderly IBD patients undergoing treatment with vedolizumab. However, our current data is primarily limited by small sample size and unequal study arm size. Also, our sample is primarily Caucasian, limiting our data's application to non-white IBD patient populations. We are currently working to combine our data with that of other hospital populations to overcome this limitation." @default.
- W2979805339 created "2019-10-18" @default.
- W2979805339 creator A5041514747 @default.
- W2979805339 creator A5088527210 @default.
- W2979805339 creator A5091668630 @default.
- W2979805339 date "2019-10-01" @default.
- W2979805339 modified "2023-09-23" @default.
- W2979805339 title "2909 Vedolizumab Safety Profile in Treatment of Elderly IBD Patients" @default.
- W2979805339 doi "https://doi.org/10.14309/01.ajg.0000601168.58694.99" @default.
- W2979805339 hasPublicationYear "2019" @default.
- W2979805339 type Work @default.
- W2979805339 sameAs 2979805339 @default.
- W2979805339 citedByCount "0" @default.
- W2979805339 crossrefType "journal-article" @default.
- W2979805339 hasAuthorship W2979805339A5041514747 @default.
- W2979805339 hasAuthorship W2979805339A5088527210 @default.
- W2979805339 hasAuthorship W2979805339A5091668630 @default.
- W2979805339 hasConcept C120665830 @default.
- W2979805339 hasConcept C121332964 @default.
- W2979805339 hasConcept C126322002 @default.
- W2979805339 hasConcept C187212893 @default.
- W2979805339 hasConcept C197934379 @default.
- W2979805339 hasConcept C2776207728 @default.
- W2979805339 hasConcept C2778260677 @default.
- W2979805339 hasConcept C2778715236 @default.
- W2979805339 hasConcept C2779134260 @default.
- W2979805339 hasConcept C2779399171 @default.
- W2979805339 hasConcept C2780479503 @default.
- W2979805339 hasConcept C2908647359 @default.
- W2979805339 hasConcept C61511704 @default.
- W2979805339 hasConcept C71924100 @default.
- W2979805339 hasConcept C90924648 @default.
- W2979805339 hasConcept C99454951 @default.
- W2979805339 hasConceptScore W2979805339C120665830 @default.
- W2979805339 hasConceptScore W2979805339C121332964 @default.
- W2979805339 hasConceptScore W2979805339C126322002 @default.
- W2979805339 hasConceptScore W2979805339C187212893 @default.
- W2979805339 hasConceptScore W2979805339C197934379 @default.
- W2979805339 hasConceptScore W2979805339C2776207728 @default.
- W2979805339 hasConceptScore W2979805339C2778260677 @default.
- W2979805339 hasConceptScore W2979805339C2778715236 @default.
- W2979805339 hasConceptScore W2979805339C2779134260 @default.
- W2979805339 hasConceptScore W2979805339C2779399171 @default.
- W2979805339 hasConceptScore W2979805339C2780479503 @default.
- W2979805339 hasConceptScore W2979805339C2908647359 @default.
- W2979805339 hasConceptScore W2979805339C61511704 @default.
- W2979805339 hasConceptScore W2979805339C71924100 @default.
- W2979805339 hasConceptScore W2979805339C90924648 @default.
- W2979805339 hasConceptScore W2979805339C99454951 @default.
- W2979805339 hasIssue "1" @default.
- W2979805339 hasLocation W29798053391 @default.
- W2979805339 hasOpenAccess W2979805339 @default.
- W2979805339 hasPrimaryLocation W29798053391 @default.
- W2979805339 hasRelatedWork W2033059461 @default.
- W2979805339 hasRelatedWork W2069424104 @default.
- W2979805339 hasRelatedWork W2076390064 @default.
- W2979805339 hasRelatedWork W2587196664 @default.
- W2979805339 hasRelatedWork W2605674307 @default.
- W2979805339 hasRelatedWork W2885490300 @default.
- W2979805339 hasRelatedWork W2972119029 @default.
- W2979805339 hasRelatedWork W3035972576 @default.
- W2979805339 hasRelatedWork W4383388333 @default.
- W2979805339 hasRelatedWork W46359855 @default.
- W2979805339 hasVolume "114" @default.
- W2979805339 isParatext "false" @default.
- W2979805339 isRetracted "false" @default.
- W2979805339 magId "2979805339" @default.
- W2979805339 workType "article" @default.